Literature DB >> 26963848

Defining problematic pharmaceutical opioid use among people prescribed opioids for chronic noncancer pain: do different measures identify the same patients?

Gabrielle Campbell1, Raimondo Bruno2, Nicholas Lintzeris3,4, Milton Cohen5, Suzanne Nielsen1, Wayne Hall6,7, Briony Larance1, Richard P Mattick1, Fiona Blyth3, Michael Farrell1, Louisa Degenhardt1,8,9,10.   

Abstract

The International Classification of Diseases (ICD) and the Diagnostic and Statistical Manual (DSM) are routinely used in diagnosing illicit substance use disorders, but for people taking prescribed opioids they remain controversial. In pain medicine, the concept of "Addiction" is preferred with reduced emphasis on tolerance and withdrawal. This article examines the prevalence and characteristics of pharmaceutical opioid dependence/disorder according to ICD, DSM, and the pain medicine concept of "Addiction," among chronic noncancer pain (CNCP) patients prescribed opioids. In the current study, we used data from a national sample of 1134 people prescribed opioids for CNCP. Past 12-month "Addiction" (based on Pain Medicine definition), DSM, and ICD dependence definitions were assessed using the Composite International Diagnostic Interview. Twenty-four percent of the cohort met the criteria for "Addiction," 18% for DSM-5 use disorder and 19% for ICD-11 dependence. There was "substantial" concordance between "Addiction" and both DSM-5 use disorder and ICD-11 dependence, although concordance was much greater with ICD-11 dependence (kappa = 0.63 and 0.79, respectively). Participants meeting the criteria for "Addiction" only were older, less likely to engage in nonadherent behaviours, self-reported fewer problems or concerns with their medication, and had lower rates of psychological distress than those who also met the DSM-5 and ICD-11 criteria. The definition of "Addiction" captures a larger group of patients than other classification systems and includes people with fewer "risk" behaviours. Despite removal of tolerance and withdrawal for prescribed opioid use for DSM-5, we found that "Addiction" was more closely related to an ICD-11 diagnosis of pharmaceutical opioid dependence.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26963848     DOI: 10.1097/j.pain.0000000000000548

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  7 in total

1.  Development of a Brief Patient-Administered Screening Tool for Prescription Opioid Dependence for Primary Care Settings.

Authors:  Suzanne Nielsen; Louisa Picco; Gabrielle Campbell; Nicholas Lintzeris; Briony Larance; Michael Farrell; Louisa Degenhardt; Raimondo Bruno
Journal:  Pain Med       Date:  2020-02-01       Impact factor: 3.750

2.  Estimated Prevalence of Opioid Use Disorder in Massachusetts, 2011-2015: A Capture-Recapture Analysis.

Authors:  Joshua A Barocas; Laura F White; Jianing Wang; Alexander Y Walley; Marc R LaRochelle; Dana Bernson; Thomas Land; Jake R Morgan; Jeffrey H Samet; Benjamin P Linas
Journal:  Am J Public Health       Date:  2018-10-25       Impact factor: 11.561

3.  Risk factors for addiction among patients receiving prescribed opioids: a systematic review protocol.

Authors:  Amber Cragg; Jeffrey P Hau; Stephanie A Woo; Christine Liu; Mary M Doyle-Waters; Corinne M Hohl
Journal:  Syst Rev       Date:  2017-12-28

4.  Combating escalating harms associated with pharmaceutical opioid use in Australia: the POPPY II study protocol.

Authors:  Natasa Gisev; Sallie-Anne Pearson; Timothy Dobbins; David C Currow; Fiona Blyth; Sarah Larney; Adrian Dunlop; Richard P Mattick; Andrew Wilson; Louisa Degenhardt
Journal:  BMJ Open       Date:  2018-12-04       Impact factor: 2.692

Review 5.  Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain.

Authors:  Frank Petzke; Thomas Tölle; Mary-Ann Fitzcharles; Winfried Häuser
Journal:  CNS Drugs       Date:  2021-11-21       Impact factor: 5.749

6.  [Long-term opioid therapy of non-cancer pain : Prevalence and predictors of hospitalization in the event of possible misuse].

Authors:  W Häuser; T Schubert; N Scherbaum; T Tölle
Journal:  Schmerz       Date:  2018-12       Impact factor: 1.107

7.  [Recommendations of the second update of the LONTS guidelines : Long-term opioid therapy for chronic noncancer pain].

Authors:  Winfried Häuser; Frietjof Bock; Michael Hüppe; Monika Nothacker; Heike Norda; Lukas Radbruch; Marcus Schiltenwolf; Matthias Schuler; Thomas Tölle; Annika Viniol; Frank Petzke
Journal:  Schmerz       Date:  2020-06       Impact factor: 1.107

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.